Ewa Antonina Bieganska

Dr. Ewa Antonina Bieganska


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
EBEwa Antonina Bieganska
Ewa Antonina Bieganska
PKPrzemyslaw Kosinski
Przemyslaw Kosinski
MWMarek Wolski
Marek Wolski
Background: The potential therapeutic role of fecal microbiota transplantation (FMT) in various diseases has been thoroughly studied over the last few decades. However, the majority of studies focus on the adult population, therefore, conclusions regarding the application of FMT in the pediatric population are much less clear. This systematic review aims to summarize the research conducted so far on the efficacy and safety of FMT in the pediatric population, assess the quality of the evidence of its effectiveness, and outline the most promising areas for future research. Methods: We performed a systematic literature search from the index date to 8 June 2024 on the Embase, PubMed, and Web of Science databases. One author screened the resulting 121 articles. Eventually, 35 eligible studies that reported FMT use in seven different diseases were identified. Results: All of the studies assessed FMT as a safe procedure without many serious adverse effects. The best-documented application, which is the only one recommended in official guidelines, is recurrent Clostridioides difficile infection. Other disease entities in which the use of FMT has been studied with good clinical effects are inflammatory bowel disease, allergic colitis, autism, Tourette syndrome, and colonization with multi-drug-resistant organisms. However, it should be noted that the majority of studies are cohort and case-control studies, without randomization, which translates into low evidence quality. In one randomized, controlled trial focusing on the effect of FMT on weight loss in obese individuals, a lack of effect was found. Conclusions: While FMT and subsequent iterations of gut microbiota-targeted interventions hold promising therapeutic potential for various disease entities in the pediatric population, the current evidence behind this conclusion is of low quality. Based on current studies, these methods appear to be both effective and safe. However, further randomized clinical trials are necessary, especially within the pediatric population, for which such studies remain scarce.

9 March 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EBEwa Antonina Bieganska
Ewa Antonina Bieganska
MWMarek Wolski
Marek Wolski
MZMagdalena Ewa Zarlenga
Magdalena Ewa Zarlenga
JBJaroslaw Bilinski
Jaroslaw Bilinski
PKPrzemyslaw Kosinski
Przemyslaw Kosinski
Background/Objectives: Necrotizing enterocolitis (NEC) is an inflammatory disease with an incidence of about one in 1000 live births, much higher in premature and low birth weight newborns. Intestinal dysbiosis is an important element in the pathogenesis of NEC, and for this reason, experimental models have been used to administer fecal microbiota transplants (FMTs) for prophylaxis and treatment of NEC with very satisfactory results. The primary endpoint of the study is safety, defined as the incidence of adverse events (AEs) and serious adverse events (SAEs) occurring from the time of intervention until hospital discharge, classified according to severity and assessed for relatedness to the intervention. Methods: This prospective, single-arm, open-label clinical study will include 20 infants born between 24 0/7 and 36 6/7 weeks of gestation. FMTs will be administered twice as a deep rectal infusion via a Foley catheter. The donors of the material from which the FMT will be prepared will be women in the third trimester of pregnancy. The safety of the therapy will be assessed by comparison with a control group, i.e., 20 patients who will meet the same inclusion criteria and will not meet any of the exclusion criteria, subject to the same hospital observation but without undergoing any medical/therapeutic intervention other than the collection of biological material. Discussion: The study will provide data on the safety and initial efficacy of FMT in this group of patients, which will allow for further research into the use of this method in the prevention of infections and NEC. Ethics: The study protocol was approved by the Bioethics Committee of the Medical University of Warsaw, Warsaw, Poland (KB/52/2025). All procedures will follow the principles of the Declaration of Helsinki. The results of the study will be submitted for knowledge translation in peer-reviewed journals and presented at national and international pediatric society conferences. Clinical Trial Registration: The study is registered at ClinicalTrials.gov: ID: NCT06333405.

24 January 2026 in Medical Science Monitor
Verified
Journal Article
Open access
JBJakub Borkowski
Jakub Borkowski
ZZZuzanna Zalewska
Zuzanna Zalewska
EBEwa Antonina Bieganska
Ewa Antonina Bieganska
MWMarek Wolski
Marek Wolski
Predictors of Recurrence in Pediatric Perianal Abscess and Fistula-In-Ano: Insights From a 5-Year Surgical Cohort Study - Article abstract #949712

9 February 2022
Verified
Journal Article
Open access
EBEwa Antonina Bieganska
Ewa Antonina Bieganska
Jan StachurskiJan Stachurski
Jan Stachurski
KRKarol Rokicki
Karol Rokicki
Paediatric trauma centers (PTCs) are facilities that were established to provide traumatised patients with fast, accurate diagnoses and optimal treatments. In Poland, they have been functioning since 2017. Our research aimed to assess the overall activity of the PTCs and cross-sectional data of their patients in Poland in 2019. We have analysed data provided by the National Health Fund (NHF) about the activity of seven trauma centers for children. For the PTC in the Paediatric Teaching Clinical Hospital University Clinical Center of the Medical University of Warsaw, we have gathered the data from the internal documentation system. In Poland, in 2019, there were seven operating PTCs. During that year, they hospitalised 195 severely traumatised patients. The available data have shown that no specialised tracking system of children admitted to PTCs was used; we have obtained data reporting final diagnoses, not the preliminary ones. Summarising the data from the PTC in Warsaw, in the first year of its operation there were 32 patients admitted, of which only 8 have met the criteria of admission. Due to the small number of patients reported, it is difficult to draw specific conclusions about the efficacy of PTCs in Poland. Obtaining reliable data is difficult, as there is no paediatric trauma patients database. To assess and improve the quality of PTCs, it would be profitable to create a national system monitoring the events and collecting data on the treatment results.